###### Significance Statement

Animal research indicates that decreased expression of brain-derived neurotrophic factor (BDNF) in the amygdala is involved in regulating anxiety and alcohol drinking behaviors. Within humans with alcohol use disorder (AUD), the relationship between BDNF levels and amygdala functioning has been unclear. The goal of the current study was to explore the links between peripheral BDNF levels, amygdala circuit function during anxiety, and drinking behaviors in humans. Results revealed that lower levels of plasma BDNF were associated with decreased functional connectivity between the amygdala and regulatory regions of the prefrontal cortex (PFC), captured via functional magnetic resonance imaging (fMRI). Within individuals with AUD, lower levels of BDNF and less amygdala-PFC connectivity during anxiety were associated with more recent binge episodes and lower age of AUD onset. The study provides evidence to suggest that plasma BDNF levels may serve as a biomarker in relation to amygdala circuit function in humans.

Alcohol use is the leading risk factor for global disease burden and has a substantial impact on physical and mental health ([@CIT0036]). In the United States, alcohol use disorder (AUD) is also highly prevalent with approximately 30% of individuals meeting criteria for the disorder at some point in their lifetime ([@CIT0035]). Consequently, there is an urgent need to better understand the pathophysiology of AUD to aid in the development of novel prevention and intervention efforts. Translational, mechanistic research designed to bridge the gap between human and nonhuman findings are especially key to move towards greater understanding and improved treatment of AUD.

Preclinical models indicate that brain-derived neurotrophic factor (BDNF) is involved in the development of AUD. BDNF is a neurotrophin that mediates neuroplasticity and the formation, survival, and differentiation of neurons in the brain through interactions with the tropomyosin-related kinase B receptor and several signaling cascades ([@CIT0078]; [@CIT0058]; [@CIT0004]). In rodents, acute alcohol administration increases BDNF messenger RNA (mRNA) expression ([@CIT0054]; [@CIT0068]), whereas prolonged excessive alcohol intake reduces BDNF, particularly in the amygdala, striatum, and medial prefrontal cortex (mPFC) ([@CIT0068]; [@CIT0017]; [@CIT0052]). Studies have also shown that haplodeficient BDNF and cyclic adenosine monophosphate (AMP) responsive-element binding protein mice showing about 50% lower BDNF levels have an increased preference for alcohol ([@CIT0038]; [@CIT0066]) and display exaggerated anxiety-like behaviors ([@CIT0066]). Inhibition of BDNF expression in the central nucleus of amygdala via administration of BDNF antisense oligodeoxynucleotides increases both alcohol consumption and anxiety, which can be rescued by subsequent BDNF co-infusion ([@CIT0067]). It has therefore been suggested that decreased BDNF levels in the amygdala are involved in regulating anxiety and alcohol consumption ([@CIT0065]; [@CIT0008]).

With regard to clinical models, our recent study using human postmortem amygdala found that individuals with early onset-AUD (i.e., onset prior to age 21 years) but not late-onset AUD (i.e., onset after age 21 years) exhibited an upregulation of BDNF antisense and a decrease in amygdala BDNF expression relative to control participants ([@CIT0009]). No other studies to our knowledge have directly measured BDNF levels in the human amygdala, although fortunately, peripheral measures of BDNF have been shown to correlate with brain levels in rodents ([@CIT0044]); thus, it is purported that BDNF measured via serum or plasma reflects (to some extent) central BDNF activity. To date, numerous studies have tested differences in serum and/or plasma BDNF levels between individuals with and without AUD and have shown that AUD is associated with both increased BDNF ([@CIT0013]; [@CIT0022]) and decreased BDNF ([@CIT0043]; [@CIT0083]; [@CIT0046]) compared with controls. An even larger set of studies showed no association between BDNF and AUD diagnoses ([@CIT0037]; [@CIT0015]; [@CIT0050]; [@CIT0073]). These discrepant findings are likely related to the fact that AUD is a heterogeneous diagnosis that can include varying symptom combinations and patterns of drinking behavior. More robust and consistent associations with BDNF may therefore be found at the level of individual differences, particularly biologically based individual differences. As has been discussed extensively in the field of genetics ([@CIT0056]), the identification of intermediate biological phenotypes that serve as a link between molecular variables and human behavior may be a way to reduce heterogeneity and improve our understanding of the role of BDNF in AUD.

BDNF promotes synaptic plasticity and connectivity in the brain ([@CIT0047]). Therefore, neural reactivity and functional connectivity measured via functional magnetic resonance imaging (fMRI) may be an important individual difference factor in humans that acts transiently and is associated with both BDNF levels and drinking behaviors. Indeed, a functional polymorphism in the BDNF gene, specifically, the valine-to-methionine substitution at codon 66 (Val66Met), is associated with alterations in functional connectivity within several large-scale neural networks during resting state ([@CIT0079]; [@CIT0080]) and emotion processing ([@CIT0062]). More broadly, Val66Met is associated with reductions in gray matter in memory and emotion regions ([@CIT0039]), exaggerated limbic activation to negative stimuli ([@CIT0062]), and deficits in cognitive function ([@CIT0023]; [@CIT0020]). There has been only 1 prior study to our knowledge that has investigated the impact of peripheral BDNF, measured in blood plasma, on functional connectivity associating increased levels of plasma BDNF with increased resting-state connectivity between motor areas in healthy older adults ([@CIT0061]). Together these data highlight BDNF's key role in neural function; however, no study to date has specifically examined the association between peripheral measures of BDNF and amygdalar functioning in humans despite the plethora of animal studies demonstrating the impact of BDNF levels in the amygdala on alcohol consumption and anxiety-like behaviors ([@CIT0048]).

The broader human neuroimaging literature clearly indicates that anxiety and alcohol abuse are associated with abnormalities in amygdala-based neural networks. Alcohol acutely dampens amygdala reactivity ([@CIT0029]; [@CIT0077]) and uncouples functional connections between the amygdala and regulatory prefrontal cortex (PFC) regions during threat perception ([@CIT0030]). When sober, individuals with AUD, and individuals at risk for AUD, show decreased amygdala reactivity to threatening stimuli ([@CIT0028]; Marinkovi et al., 2009). Decreased amygdala-PFC connectivity at rest has also been shown to longitudinally predict increases in alcohol use in adolescents ([@CIT0070]). Taken together, the amygdala is implicated in alcohol dependence in both human and animal research, and the amygdala-PFC circuit, in particular, is a well-positioned target for the effects of varying BDNF levels.

The current study examined whether human plasma BDNF was related to individual differences in amygdala reactivity and amygdala-PFC functional connectivity during a task specifically designed to elicit anxiety and whether both BDNF levels and amygdala-circuit function were associated with real-world drinking behaviors. The sample included individuals with and without AUD in order to capture a full distribution of drinking behaviors, BDNF levels, and individual differences in amygdala reactivity and functional connectivity. Individuals completed a neuroimaging paradigm designed to probe both reactivity during anticipatory anxiety and fear using unpredictable (U-) and predictable (P-) threat of electric shock, respectively. Human and animal studies show that anticipatory anxiety and fear are separable aversive states that have overlapping, yet distinct, neural correlates ([@CIT0018]; [@CIT0002]). Notably, recent research found that the BDNF Val66Met polymorphism is associated with exaggerated anticipatory anxiety to an upcoming stressor ([@CIT0014]), and exaggerated anticipatory anxiety, but not fear reactivity, distinguished individuals with AUD from controls ([@CIT0031], [@CIT0032]). Here, we investigated changes in plasma BDNF levels and amygdala reactivity and amygdala-PFC functional connectivity, particularly during anticipatory anxiety (i.e., U-threat) and their association with greater real-world problem-drinking behaviors.

METHODS {#s1}
=======

Participants {#s2}
------------

Volunteers were recruited via advertisements posted in the Chicago community, local psychiatric clinics, and nearby college campuses. To be included in the study, individuals were required to be between 21 and 30 years old and able to provide written informed consent. Individuals also had to (1) have no personal or family history of AUD (i.e., controls) or (2) meet criteria for AUD within the past 2 years. Exclusion criteria included any serious medical condition, psychotropic medication use, deafness, contraindication for neuroimaging, pregnancy, lifetime moderate or severe substance use disorder (other than alcohol and nicotine), daily cigarette smoking, and psychosis. The protocol was approved by the university institutional review board and participants provided written informed consent. Individuals were instructed to abstain from drugs and alcohol 24 hours prior to the laboratory assessments, which was verified via breath alcohol and urine screens. Participants were monetarily compensated for their time. A total of 37 individuals with AUD and 24 controls enrolled in the study and completed all laboratory procedures (total *n* = 61). A total of 4 individuals had excessive motion during the fMRI scan (i.e., \<2.5-mm displacement in any direction) and were excluded from analyses (3 AUD subjects and 1 control) for a final sample of 57 individuals. Please see [Table 1](#T1){ref-type="table"}for participants' demographics and clinical characteristics.

###### 

Demographics and clinical characteristics

                                           AUD (n = 33)   Controls (n = 24)   Combined (n = 57)
  ---------------------------------------- -------------- ------------------- -------------------
  Demographics                                                                
  Age (years)                              23.6 (2.8)     24.0 (2.6)          23.8 (2.7)
  Sex (female)                             39.4%          54.2%               45.6%
  Ethnicity (Hispanic)                     30.3%          8.3%                21.1%
  Race                                                                        
  White                                    66.7%          45.8%               56.1%
  Black                                    3.0%           16.7%               8.8%
  Asian                                    6.1%           29.2%               15.8%
  Native Hawaiian                          3.0%           0.0%                1.8%
  American Indian or Alaskan Native        3.0%           0.0%                1.8%
  Other                                    18.2%          8.3%                15.7%
  Clinical variables                                                          
  Drinks per week                          10.0 (7.2)     4.0 (5.8)           7.5 (7.2)
  Number of binge episodes                 8.3 (6.1)      2.4 (4.6)           5.2 (6.0)
  AUD age of onset                         19.5 (2.8)     --                  19.5 (2.8)
  Daily cigarette smoker                   0.0%           0.0%                0.0%
  No. times used cannabis                  0.2 (0.6)      0.2 (0.6)           0.2 (0.6)
  No. times used \*other illicit drugs     0.2 (1.3)      0.04 (0.2)          0.2 (0.9)
  BDNF variable                                                               
  Plasma BDNF (pg/μL)                      47.0 (11.2)    40.4 (8.8)          44.2 (10.7)
  Diagnostic variables                                                        
  Current major depressive disorder        9.1%           8.3%                8.8%
  Lifetime major depressive disorder       24.2%          16.7%               21.1%
  Current anxiety disorder                 12.1%          8.3%                10.5%
  Lifetime anxiety disorder                27.3%          16.7%               22.8%
  Current posttraumatic stress disorder    0.0%           4.2%                1.8%
  Lifetime posttraumatic stress disorder   0.0%           4.2%                1.8%

All values are means, standard deviations, unless otherwise notes.

Abbreviation: BDNF, brain derived neurotrophic factor.

Clinical Assessments and Procedure {#s3}
----------------------------------

Participants completed 2 laboratory visits separated by 1--7 days. The first visit included a clinical interview, a battery of self-report questionnaires, a blood draw, and a set of psychophysiological tasks. The second visit involved fMRI data collection. At the initial session, lifetime psychopathology was assessed via the Structured Clinical Interview for DSM-5 Disorders (American Psychiatric Association, 2015), in-person, by trained assessors and supervised by a clinical psychologist. Age of onset of AUD was recorded during the Structured Clinical Interview for DSM-5 Disorders interview and examined in the current study given that lower age of onset is associated with worse AUD prognosis ([@CIT0005]; [@CIT0025]), and BDNF expression in the amygdala is decreased in individuals with early, but not late, AUD onset ([@CIT0009]). Participants also completed a detailed assessment of their recent alcohol use employing the Timeline Follow-Back technique (Sobell and [@CIT0076]). Participants were presented with a calendar of the past 60 days, marked with holidays and special events, and were asked to indicate on what days they drank and how many drinks they consumed on each occasion. Using the Timeline Follow-Back technique, we calculated average number of drinks consumed per week and total number of binge episodes over the past 60 days. Binge episodes were defined as consuming ≥5 standard drinks for men and ≥4 drinks for women in 1 sitting.

Blood Collection and BDNF Protein Measurement {#s4}
---------------------------------------------

Each participant provided 40 mL of whole blood, which was collected via a trained phlebotomist. All blood draws occurred between the hours of 10 [am]{.smallcaps} and 1 [pm]{.smallcaps}. Blood samples were collected in K2EDTA-coated tubes and centrifuged 700 rpm for 10 minutes at 4°C. Plasma supernatant was subsequently transferred to a clean tube and immediately frozen at −80°C until use. In preparation for protein measurement, plasma samples were thawed on ice, clarified via a 20-minute spin at 10 000 g at 4°C for complete platelet removal, and supernatant transferred to new tube. BDNF levels were ascertained using a quantitative in vitro enzyme-linked immunosorbent assay kit (BioVision, Milpitas, CA). Briefly, 100 µL of BDNF standards (0.066--16 pg/uL recombinant human BDNF) were applied in duplicate to 96-well plates precoated with an antibody specific for human BDNF. The samples were diluted (1:10) and 100 µL was added to the plate in duplicate. The plate was sealed and incubated overnight at 4°C. The next morning, the plate was rinsed with wash-buffer 4 times and incubated with biotinylated primary antiserum at room temperature with gentle shaking for 1 hour. Wells were washed again, incubated with a streptavidin-HRP complex for 45 minutes and developed in a solution of tetramethylbenzidine for 20 minutes in the dark prior to stopping the reaction with a 2N sulfuric acid stop solution. Samples and standards were run in duplicate and replicated across a minimum of 2 enzyme-linked immunosorbent assays. The optical density of each sample and standard was measured at 450 nm using the Spectra MR microplate reader (Dynex Technologies, Chantilly, VA), and the amount of BDNF in each sample was calculated against the BDNF standard curve and expressed as pg/uL of protein.

fMRI Threat Task {#s5}
----------------

Prior to the task, electrodes were placed on participants' left foot and a shock work-up was completed to identify the level of shock intensity each participant described as "highly annoying but not painful" (between 1 and 5 mA). The task was designed to be analogous to the widely used NPU-threat task described by [@CIT0074]. There were 3 within-participant conditions: N, P shock, and U shock. During each condition, participants viewed a numeric countdown that ranged between 3 and 8 seconds (*M* =* *5 seconds). Text at the bottom of the computer monitor informed participants of the current condition. During N, no shocks were delivered and the text read "no shock." During P, participants received a shock only when the countdown reached "1" and the text read "shock at 1". During U, participants received a shock at random, regardless of the number on the screen and the text read "shock at anytime." Following each countdown, individuals saw a fixation cross for 5 to 7 seconds (*M* = 6 seconds). N, P, and U countdowns were presented in blocks of 6, and each condition/block was administered in a randomized order (counterbalanced) 6 times over the course of 2 runs. Notably, not all countdowns ran full-length or terminated with "1," allowing us to match the 3 conditions on total number of data points (i.e., TRs/repetition times). Participants received 10 electric shocks during P and 10 electric shocks during U during each run. The rate of "shock at 1" during the P condition was 60%, consistent with the NPU version used by Grillon and colleagues ([@CIT0074]).

fMRI Data Collection and Processing {#s6}
-----------------------------------

fMRI was performed on a 3.0 Tesla GE MR 750 scanner (General Electric Healthcare, Waukesha, WI) using an 8-channel phased-array radio frequency head coil. A standard T2-sensitive gradient-echo echoplanar imaging sequence was used (2 seconds TR; 22.2 milliseconds TE; 90° flip; 64 × 64 matrix; 22 cm FOV; 44 axial slices; 3.44 × 3.44 × 3.0 mm voxels; 336 volumes).

All fMRI data met criteria for high quality and scan stability with minimum motion correction (i.e., \<2 mm displacement in any direction). Preprocessing of fMRI data was conducted using Statistical Parametric Mapping software (SPM12, Wellcome Department of Imaging Neuro-Science, London, UK), and, accordingly, we followed the standard preprocessing routines suggested by SPM. The first 4 volumes were discarded to allow for T~1~ equilibration effects. Images were slice time corrected with the reference slice based on the middle of each TR, realigned with the first volume to correct for head motion, co-registered to the participants' T~1~-weighted image in Montreal Neurological Institute (MNI) space, re-sampled to 2-mm^3^ voxels, and smoothed using a 8-mm isotropic Gaussian kernel. The general linear model was applied to the time series, convolved with the canonical hemodynamic response function and with a 128-second high-pass filter. Condition effects for U, P, and N anticipation were separately estimated at each voxel for each participant. For each condition, the countdowns prior to the shock, or prior to trial termination in instances where there was no shock, were modeled. Of note, we conducted an additional set of analyses where the U- and P-shocks were included as regressors in the first level model. The results of the paper were consistent whether shocks were included or excluded from the model. Movement parameters obtained during realignment were included in the model as regressors of no interest to account for motion-related effects on BOLD. Individual contrast maps for U-threat \> no-threat (i.e., anticipatory anxiety) and P-threat \> no-threat (i.e., fear) were created for each participant.

For functional connectivity, we used a seed-based, generalized form of context-dependent psychophysiological interaction (PPI) analyses (<http://brainmap.wisc.edu/PPI>, [@CIT0055]), with left and right anatomical amygdala masks (created using AAL atlas) as the seeds of interest. The de-convolved time series from the amygdala masks were extracted for each participant to create the physiological variables. The condition onset times for U-threat, P-threat, and no-threat were separately convolved with the canonical hemodynamic response function (HRF) for each condition, creating the psychological regressors. The interaction terms (PPIs) were computed by multiplying the time series from the psychological regressors with the physiological variable. Activity within the amygdala was then regressed on a voxel-wise basis against the interaction, with the physiological and psychological variables serving as regressors of interest. Individual U-threat \> no-threat and P-threat \> no-threat PPI images were created for every participant.

Data Analysis Plan {#s7}
------------------

To examine whether BDNF was associated with amygdala reactivity, we used a focused, region-of-interest analysis approach. We entered the U-threat \> no-threat and P-threat \> no-threat images into separate 1-sample *t* tests. Then we extracted mean task activation parameter estimates (*β*-weights; arbitrary unit) from separate left and right whole anatomical amygdala masks (created using AAL atlas) from each model (U-threat and P-threat). Using Pearson's correlations, we assessed whether plasma BDNF levels were associated with focal left and right amygdala reactivity during U-threat and P-threat.

To examine the impact of BDNF on amygdala-PFC functional connectivity, the U-threat \> no-threat and P-threat \> no-threat images were entered into 2 separate 2nd-level 1-sample *t* tests with individual BDNF values as a regressor. To determine our fMRI significance threshold, we applied an anatomically derived (AAL atlas) partial brain mask of the entire PFC to our data (search volume = 451 840 mm^3^, encompassing 56 480 voxels). The search for significant results was restricted to the PFC given our strong a priori hypotheses regarding frontolimibic connectivity. Cluster-based significance thresholding was used to adjust for multiple comparisons within the search volume using Monte Carlo simulations (10 000 iterations) performed with the most up-to-date version of 3dClustSim, an adaptation of AlphaSim (<https://afni.nimh.nih.gov/pub/dist/doc/program_help/3dClustSim.html>) in AFNI (19.2.06). The mixed autocorrelation function was utilized to give an accurate estimation of non-Gaussian noise structure ([@CIT0090]). A family wise error correction at α \< 0.05 was achieved for voxel threshold of *P \< *.005 with minimum cluster size of 233 contiguous voxels. Connectivity parameter estimates from 8-mm-radius spheres surrounding peak activations within the PFC associated with BDNF levels were then extracted for further analysis.

We next examined whether BDNF levels and the significant neural findings (reactivity and/or connectivity) identified above correlated with real-world drinking behaviors, particularly average number of drinks per week and total number of binge episodes in the past 60 days. We also examined associations with age of AUD onset within individuals with an AUD diagnosis. We conducted a series of Pearson's correlations between plasma BDNF and peak significant parameter estimates and drinking behaviors. A total of 9 correlations were run. A *P* value correction for multiple comparisons was not applied in order to comprehensively test relationships with several drinking variables (i.e., drinks per week, binge episodes, and AUD age of onset).

Although the aims of the current study were dimensional, participants were recruited into 2 groups: individuals with AUD and controls. Therefore, post-hoc we tested whether group (AUD vs control) moderated any of the above associations. Similarly, the study included males and females and we therefore examined the moderating impact of biological sex. For each set of analyses (1: BDNF and amygdala reactivity; 2: BDNF and amygdala-PFC connectivity; and 3: correlations with drinking behaviors), we tested the impact of group and sex using hierarchical linear regression where group, sex, and the independent variable were entered in Step 1, and the 2-way interactions between group and the independent variable, and sex and the independent variable, were entered in Step 2. Significant interactions were followed-up using standard simple slopes approach ([@CIT0001]).

Lastly, we explored whether significant results were affected by 2 key variables/covariates: time (in days) between BDNF data collection and the fMRI session (for BDNF models only) and lifetime diagnosis of any major internalizing disorder (yes/no) defined as major depressive disorder, social anxiety disorder, panic disorder, specific phobia, agoraphobia, generalized anxiety disorder, and/or post-traumatic stress disorder. Correlations were run as partial correlations controlling for time and diagnosis. For linear regression analyses, covariates were entered in Step 1 of the model.

RESULTS {#s8}
=======

BDNF and Amygdala Reactivity {#s9}
----------------------------

Whole-brain task activation patterns for individuals with and without AUD are reported in [@CIT0034]. In the current study, there were no significant associations between BDNF levels and amygdala reactivity to U-threat or P-threat (*r*s: −.07 to .07, *P* \> .61). Group (AUD vs no AUD) and sex did not moderate any of the null associations between BDNF levels and amygdala reactivity (*P* \> .26).

BDNF and Amygdala Functional Connectivity {#s10}
-----------------------------------------

During U-threat, lower levels of plasma BDNF were associated with less functional connectivity between the left amygdala and the medial PFC (mPFC) (MNI peak \[10, 62, 10\], *Z* = 3.14, *k* = 2480 mm^3^, *P *=* *.001; [Figure 1A](#F1){ref-type="fig"}) and the left amygdala and the left inferior frontal gyrus (IFG) (MNI peak \[−42, 32, 0\], *Z* = 3.47, *k* = 5104 mm^3^, *P *=* *.0001; [Figure 1B](#F1){ref-type="fig"}). There were no other significant associations during U-threat or any significant BDNF and functional connectivity associations during P-threat. Group and sex did not moderate the association between BDNF and amygdala-mPFC connectivity (group: *β* = 0.23, *t* = 0.81, *P* = .42; sex: *β* = 0.06, *t* = 0.09, *P* = .93) or amygdala-IFG connectivity (group: *β* = −0.12, *t* = −0.44, *P* = .66; sex: *β* = 0.15, *t* = 0.23, *P* = .82) during U-threat.

![Top of the figure displays the left and right anatomical amygdala seed-regions-of-interest (SOIs). Top of panel (A) shows a statistical t-map on a canonical brain illustrating the significant correlation between plasma brain-derived neurotrophic factor (BDNF) levels and left amygdala and medial prefrontal cortex (mPFC) connectivity during unpredictable threat (U-threat). Bottom of panel (A) displays a scatter plot of the correlation (*P* \< .05) between plasma BDNF levels and extracted parameter estimates of amygdala-mPFC functional connectivity. Top of panel (B) shows a statistical t-map on a canonical brain illustrating the significant correlation between plasma BDNF levels and left amygdala and left inferior frontal gyrus (IFG) connectivity during unpredictable threat (U-threat). Bottom of panel (B) displays a scatter plot of the correlation (*P* \< .05) between plasma BDNF levels and extracted parameter estimates of amygdala-IFG functional connectivity. (n = 24 controls; 33 alcohol use disorder \[AUD\] participants).](pyz057f0001){#F1}

Associations With Drinking Behaviors {#s11}
------------------------------------

As a group, individuals with AUD had higher levels of plasma BDNF compared with controls (*F*\[1, 56\] = 5.60, *P *=* *.02). Across the entire sample, there were no associations between plasma BDNF levels and average number of drinks per week (*r* \< 0.01, *P* = .98) or number binge episodes in the past 60 days (*r* = −0.08, *P* = .57). However, group (AUD vs controls) moderated the association between plasma BDNF levels and number of binge episodes (*β* = 0.68, *t* = 2.93, *P *=* *.01) such that within individuals with AUD, lower BDNF was associated with more binge episodes (*β* = −.51, *t* = −3.09, *P* = .02; [Figure 2A](#F2){ref-type="fig"}), but within individuals without AUD there was no association between BDNF levels and binge episodes (*β* = .44, *t* = 1.33, *P* = .18). Group did not moderate the association between BDNF and drinks per week (*β* = −1.07, *t* = −1.66, *P* = .10). Sex did not moderate the association between BDNF and drinks per week (*β* = 0.12, *t* = 0.20, *P* = .84) or number of binge episodes (*β* = −0.07, *t* = −0.12, *P* = .91). Results within the AUD group only also revealed that lower BDNF was associated with lower age of AUD onset (*r* = .40, *P* = .02; [Figure 2C](#F2){ref-type="fig"}).

![Scatter plots of the significant correlations. Top panel shows the association between number of binges in the past 60 days and plasma brain-derived neurotrophic factor (BDNF) levels (*P* = .01) (A) and amygdala-medial prefrontal cortex (mPFC) functional connectivity during unpredictable threat (U-threat) (*P* = .02) (B). Bottom panel shows the association between alcohol use disorder (AUD) age of onset and plasma BDNF levels (*P* = .02) (C) and amygdala-mPFC functional connectivity during U-threat (*P* = .03) (D). n = 33 AUD subjects.](pyz057f0002){#F2}

Given the null amygdala reactivity findings, we only explored links between drinking behaviors and significant peak functional connectivity parameter estimates associated with BDNF levels (i.e., mPFC and IFG). Results revealed no associations across the entire sample between amygdala-mPFC connectivity and average number of drinks per week (*r* \< 0.01, *P* = .98) or number of binge episodes (*r* = −0.05, *P* = .73). There were also no associations between amygdala-IFG connectivity and drinks per week (*r* = −0.02, *P* = .87) or number of binge episodes (*r* = −0.09, *P* = .50). However, group moderated the association between amygdala-mPFC connectivity and number of binge episodes (*β* = −0.40, *t* = −2.52, *P* = .02). Within individuals with AUD, less amygdala-mPFC connectivity was associated with more binges (*β* = −0.48, *t* = −2.55, *P* = .01; [Figure 2B](#F2){ref-type="fig"}) and within controls, there was no association between amygdala-mPFC connectivity and binge episodes (*β* = 0.15, *t* = 1.25, *P* = .22). Group did not moderate the association between amygdala-mPFC connectivity and drinks per week or the association between amygdala-IFG connectivity and either drinking variable (*P* \> .15). Sex also did not moderate any of the tested associations (*P* \> .38). Results within the AUD group indicated that lower amygdala-mPFC connectivity was associated with younger age of AUD onset (*r* = .39, *P* = .03; [Figure 2D](#F2){ref-type="fig"}).

Impact of Potential Covariates {#s12}
------------------------------

All significant analyses were re-run controlling for time (in days) between BDNF data collection and the fMRI session and lifetime diagnosis of any major internalizing disorder (yes/no). The results indicated that neither covariate had a significant impact on the pattern of results, and the findings were identical in each covariate model.

Discussion {#s13}
==========

The primary aim of the study was to test whether plasma BDNF levels were associated with individual differences in amygdala reactivity and amygdala-PFC functional connectivity during 2 forms of aversive responding: anticipatory anxiety elicited by U-threat and fear elicited by P-threat. We also examined whether BDNF levels and our neural findings were associated with real-world drinking behaviors. Results obtained revealed that during U-threat, but not P-threat, lower levels of BDNF were associated with less functional connectivity between the left amygdala and both the mPFC and IFG. In addition, within individuals with AUD (only), lower levels of BDNF and amygdala-mPFC functional connectivity during U-threat were associated with more binge episodes within the past 60 days and a younger age of AUD onset. There were no associations with drinking behaviors in individuals without AUD. In addition, there were no associations between BDNF levels and amygdala task-based reactivity. Together, the results indicate that plasma BDNF levels are related to amygdala-PFC circuit functioning in humans, particularly during anticipatory anxiety, and these individual differences may contribute to drinking behaviors.

Across all participants, lower levels of BDNF were associated with decreased amygdala-mPFC and amygdala-IFG functional connectivity during anticipatory anxiety. These findings were observed in the absence of any direct associations between BDNF levels and amygdala reactivity, which is noteworthy in light of studies highlighting that measures of neural networks are more predictive than single regions of interest (e.g., [@CIT0010]). The amygdala networks identified in the current study include the mPFC and IFG, which are 2 key regions involved in emotion regulation and have been shown to exhibit regulatory influences on the amygdala during the inhibition of anxiety and negative affect ([@CIT0006]; [@CIT0063]). More specifically, prior studies have shown that healthy individuals exhibit greater functional coupling between the amygdala and the mPFC and IFG during threat ([@CIT0071]) and that greater connectivity is associated with greater affect regulation efficiency ([@CIT0006]). Meanwhile, individuals characterized by high levels of chronic anxiety (e.g., posttraumatic stress disorder, generalized anxiety disorder) evidence decreased functional connectivity between the amygdala and the mPFC/IFG ([@CIT0075]; [@CIT0021]). Together, these studies suggest that decreased amygdala-PFC connectivity reflects deficiencies in downregulating negative affect. Individuals with lower levels of BDNF may therefore have difficulty modulating anticipatory anxiety, particularly in the context of a U-threat. This emotion regulation deficit could be 1 potential mechanism that contributes to the link between BDNF levels and multiple forms of psychopathology ([@CIT0003]; [@CIT0065]).

The mPFC also plays an essential role in assessing risk and determining the subjective value of uncertain outcomes ([@CIT0082]) and has repeatedly been shown to be engaged during times of uncertainty ([@CIT0041]; [@CIT0049]). Cross-talk between the amygdala and mPFC is necessary for effectively coding subjective value ([@CIT0051]), and decreased functional connectivity between these regions could reflect abnormal salience processing of unpredictable threat cues. Thus, a complementary or potentially alternative hypothesis is that individuals with lower levels of BDNF exhibit impairments in appraising the relative danger vs safety of the U-threat conditions and determining threat salience.

This is the first study, to our knowledge, to examine associations between plasma BDNF levels and amygdala circuit function during fear and anxiety states in humans, although prior studies have examined whether differences in BDNF polymorphisms are associated with patterns of functional connectivity, especially during resting state. At rest, Val66Met carriers (who may be deficient in BDNF) show abnormalities across several large-scale circuits, including the default-mode network, executive control network, and salience network ([@CIT0079]; [@CIT0042]). A few studies have also reported amygdala abnormalities including increased connectivity between the amygdala and insula ([@CIT0081]). It is therefore possible that individual differences in BDNF expression have more widespread impact on brain function, and the nature of this impact depends on environmental and emotional context (e.g., resting-state vs U-threat).

We originally hypothesized that lower levels of BDNF and decreased amygdala-PFC functional connectivity would be associated with real-world problem drinking behaviors across all participants. However, within the AUD group, lower levels of BDNF and decreased amygdala-mPFC functional connectivity during U-threat were associated with more binge episodes in the past 60 days and a lower age of AUD onset, whereas there were no associations with drinking behaviors in controls. One factor that may have contributed to the moderating effect of group is the fact that the controls reported very low levels of alcohol consumption, resulting in a restricted range of drinking behaviors, whereas individuals with AUD reported substantial variability in their patterns of alcohol use. Although the purpose of including both controls and individuals with AUD in the sample was to capture a normal variable distribution to increase statistical power for dimensional analyses, in terms of the drinking behaviors, almost all of the variability was found in those with AUD. With that said, it is also worth highlighting that [@CIT0045] similarly found that plasma BDNF levels were negatively correlated with drinks consumed per day but only in individuals who exceeded 3 or more drinks per day. Thus, it is possible that specific associations between BDNF, neural function, and alcohol abuse are only observed in heavy drinkers.

Although BDNF and drinking variables were negatively associated with each other, we found that on average, individuals with AUD had higher levels of plasma BDNF compared with controls. This is consistent with a handful of other human studies ([@CIT0013]; [@CIT0022]) and highlights the heterogeneous nature of the AUD diagnosis. The current set of findings, as a whole, reinforces the utility of examining individual differences at the biological level to improve understanding of molecular, neural, and behavioral relationships.

The links between the biological and alcohol-related variables in individuals with AUD are therefore important. Binge drinking and earlier age of AUD onset are 2 indicators of AUD severity as both variables are associated with poorer AUD prognosis and a host of negative biopsychosocial outcomes ([@CIT0012]; [@CIT0024]). Lower levels of plasma BDNF and decreased amygdala-PFC functional connectivity during U-threat may be 2 related individual difference factors that contribute to these specific aspects of AUD severity. Interestingly, separate studies have previously found associations between earlier age of AUD onset and lower levels of BDNF in amygdala ([@CIT0009]) and decreased amygdala-PFC functional connectivity ([@CIT0069]). Increased alcohol consumption has also previously been associated with decreased amygdala-PFC functional connectivity ([@CIT0040]) and lower peripheral BDNF levels ([@CIT0045]), though the majority of human studies report no associations between BDNF levels and drinking behaviors (e.g., [@CIT0043]; [@CIT0026]). The current study demonstrates for the first time, to our knowledge, associations across these variables within the same sample and suggests that within individuals with AUD, BDNF, and amygdala-mPFC functional connectivity during U-threat relate to more risky and chronic patterns of alcohol abuse.

Given the current pattern of results, targeting amygdala-mPFC functional connectivity, particularly during anxiety, via BDNF expression (or other strategies) may improve drinking outcomes. As briefly noted, decreased BDNF levels in the mPFC and amygdala have been implicated in excessive alcohol use ([@CIT0052]; [@CIT0068]; [@CIT0059]). In animals, infusion of BDNF or increasing BDNF via inhibition of miRNAs in the mPFC decreases alcohol consumption ([@CIT0016]) and cocaine self-administration ([@CIT0007]), and BDNF infusion in the amygdala attenuated anxiety-like behaviors during ethanol withdrawal in rats ([@CIT0068]). The amygdala-mPFC circuit is therefore a potential key treatment target for novel AUD interventions.

The relationship between plasma BDNF levels and amygdala-PFC connectivity during U-threat, but not P-threat, is noteworthy. Anxiety and fear are separable aversive states ([@CIT0018]), and accumulating research suggests that exaggerated anticipatory anxiety during U-threat is uniquely involved in the pathophysiology of AUD ([@CIT0033]; [@CIT0057]). We have repeatedly demonstrated that individuals with both current and remitted AUD display exaggerated behavioral and neural reactivity to U-threat, but not P-threat, compared with controls ([@CIT0033]; Gorka et al., in press). It has also been shown in humans that acute alcohol administration selectively and preferentially dampens aversive reactivity to U-threat relative to P-threat ([@CIT0060]; [@CIT0011]). Targeting neural dysfunction during U-threat, specifically, may therefore have the most robust impact on alcohol behaviors.

The current study had numerous strengths but also several limitations. First, blood samples for plasma BDNF extraction were collected 1--7 days prior to the fMRI session, and this time lag in data collection may have introduced unknown confounds in the association between BDNF levels and amygdala reactivity and connectivity. There were also unmeasured factors, known to influence BDNF expression, which could have contributed to BDNF levels on the day of extraction (e.g., sleep deprivation; [@CIT0027]). To capture a more reliable estimate of BDNF levels, repeated measurements, spaced in time, would be beneficial. Second, we restricted our analyses to the amygdala and amygdala-PFC circuit given the robust animal literature implicating dysfunction in these areas; however, it is possible that other neural regions and circuits are also related to individual differences in plasma BDNF. Third, the total sample size was modest and subgroup cell sizes for AUD compared with controls was small. This issue limited statistical power and may have prevented the detection of additional associations. Lastly, the current study was correlational, and we are unable to make inferences about the directionality of the associations between BDNF, functional connectivity, and drinking behaviors. Related, to comprehensively test associations across study measures, corrections for multiple comparison were not applied to the correlations between biological variables and drinking behaviors. These results should therefore be interpreted with caution and require replication.

Results from the current study suggest that lower levels of plasma BDNF are associated with disruptions in amygdala-PFC functional connectivity during anticipatory anxiety and that these biological individual difference factors may contribute to risky patterns of alcohol use within individuals with AUD and may serve as a biomarker for AUD. Converging evidence across human and animal research suggests that the amygdala-PFC circuit is an important AUD treatment target, which may be modulated by BDNF expression.
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^1^We conducted an additional set of analyses where the U- and P- shocks were included as regressors in the first level model. The results of the paper were consistent whether shocks were included or excluded from the model.
